Proposed REINVENT4 pipeline for reversing the SASP signature
An abstract describes a proposed generative-design pipeline, trained on real LINCS L1000 data, aimed at reversing the 125-gene Sen-May signature of the senescence-associated secretory phenotype (SASP). [1]
Automatic summary · not editorially reviewed
The key findings
The abstract describes a proposed generative-design strategy applied to senescence/SASP reversal for the first time. [1]
Sen-May is named as a validated 125-gene transcriptomic signature for the SASP. [1]
A reward oracle was trained on real LINCS L1000 data covering 21299 compounds, with a scaffold-split Pearson r of 0.26. [1]
The source at a glance
- Study type / format
- Preprint abstract describing a proposed computational generative-design pipeline
- Population / context
- Computational model trained on LINCS L1000 transcriptomic data for 21299 compounds; no human or animal participants described.
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- September 29, 2026
SASP signature and the proposed design strategy
The abstract states that cellular senescence contributes to aging and age-related disease partly through the SASP. It names Sen-May as a validated 125-gene transcriptomic signature for the SASP. The authors say signature-reversal-guided generative molecular design has recently been validated at scale for other disease-associated transcriptional phenotypes, and that they apply this strategy to senescence/SASP reversal for the first time. This is a proposed computational approach, not a tested treatment.
Supporting source [1]
Training on 21299 LINCS L1000 compounds
Using the open-source tool REINVENT4, the authors trained a reward oracle directly on real Library of Integrated Network-based Cellular Signatures (LINCS) L1000 transcriptomic data covering 21299 compounds. The abstract reports a scaffold-split Pearson r = 0.26; the sentence is cut off at the permutation p value, so the full statistical result is not available in the supplied text. A correlation of this size describes how well the model predicted held-out compounds, not whether any compound reverses SASP in cells or organisms.
Supporting source [1]
Abstract-only scope of this pipeline report
The supplied text is an abstract; the full text was not reviewed. It reports model training and a correlation but no experimental validation, no tested compounds, no cells or animals and no human outcomes. The abstract does not state a sample of participants, a follow-up period or a clinical endpoint. Whether the proposed pipeline yields any compound that reverses the SASP signature remains untested in the supplied text.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The supplied text ends mid-sentence at the permutation p value, so the complete statistical result is unavailable. No experimental validation, tested compounds, cells, animals or human outcomes are reported.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Uysal SA. · europepmc.org · September 29, 2026